Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous ...

Argenx (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the US, Japan, China, the Netherlands, and internationally.

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...

VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than ...

European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...

The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...

Drug treatment for CIDP currently relies on corticosteroids, high-dose intravenous immune globulins – including Takeda’s HyQvia, which was approved for CIDP by the FDA in January – or a ...

At the moment, drug treatment for CIDP relies on corticosteroids or high-dose intravenous immune globulins, such as Takeda’s Hyqvia and Gammagard Liquid, or a procedure called plasmapheresis ...

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company announced that the European Commission ...

ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...